ClinicalTrials.gg
Not yet recruitingNCT07559240Updated May 8, 2026

A Pharmacokinetic Study of HDM1005 Injection in Participants With Impaired Renal Function and Healthy Participants

A Phase 1 interventional study of HDM1005 in Overweight and Obese, sponsored by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-08.

Sponsored by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (part of Huadong Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies in Overweight by Huadong Medicine Co., Ltd. — 7 open to participants now, 8 under way, 2 of them phase 3. Overweight · Huadong Medicine Co., Ltd..

Planned enrollment
9th of 10
30 · median 96
Started
2026
with 2 others
Phase 1
7 of 10
4 open now
Registered
9th of 10
by date

Among the 10 studies in Overweight by Huadong Medicine Co., Ltd., this one is the 9th largest by planned enrollment, is one of 3 that started in 2026, is one of 7 in phase 1, and was the 9th registered.

Overweight

3,613 studies on the registry are indexed under Overweight; 856 are open to participants now.

Browse Overweight studies →

Open to participants now

7 of the 10 studies in Overweight by Huadong Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 531 Overweight studies recruiting now, 159 (30%) set no upper age limit and 344 (65%) stop at 75 or younger; 63 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Overweight by Huadong Medicine Co., Ltd., or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the pharmacokinetic profile and safety of a single subcutaneous injection of HDM1005 solution in participants with impaired kidney function compared to healthy participants.

03

Conditions studied

  • Overweight
  • Obese
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged between 18 and 75 years (inclusive), regardless of gender.
  • Body weight ≥50.0 kg for males and ≥45.0 kg for females; (BMI) between 19.0 and 35.0 kg/m² (inclusive).
  • For participants with renal impairment: prior diagnosis of chronic kidney disease (CKD). Absolute calculated by CKD-EPI and BSA formula: ≥30 and \<60 mL/min for moderate impairment; ≥15 and \<30 mL/min for severe impairment.
  • For participants with normal renal function: aged 18 to 75 years (inclusive); body weight ≥50.0 kg (male) or ≥45.0 kg (female); BMI 19.0-35.0 kg/m².
  • In the investigator's opinion, suitable for the study based on medical history, clinical laboratory tests, vital signs, 12-lead , and physical examination at screening.
  • Provide signed before any trial procedures; fully understand the trial content, procedures, and possible adverse reactions.
  • Able to communicate well with the investigator and understand and comply with all study requirements.

Exclusion criteria

Exclusion Criteria:

  • Personal or family history of medullary thyroid carcinoma (MTC), thyroid C-cell hyperplasia, or multiple endocrine neoplasia type 2 (MEN2).
  • History of chronic pancreatitis, or an episode of acute pancreatitis or acute cholecystitis within 3 months prior to screening.
  • Severe hypoglycemic events or recurrent hypoglycemic events (≥3 episodes per week) within 3 months prior to screening.
  • For the renal impairment group: presence of obstructive urinary tract disease, acute kidney injury, or other systemic diseases beyond chronic kidney disease and its complications, which in the investigator's opinion make the participant unsuitable. For the normal renal function group: presence of clinically significant diseases involving any of the following systems at screening (including but not limited to respiratory, circulatory, digestive, hematopoietic, endocrine, immune, skin, nervous, psychiatric, ear-nose-throat, etc.), which in the investigator's opinion make the participant unsuitable.
  • Known intolerance or allergy to GLP-1R and/or GIPR agonists, or known allergy to HDM1005 or any component of the formulation.
  • Major surgery within 6 months prior to screening, or incomplete healing of surgical incisions, or planned surgery during the study.
  • Blood donation or blood loss ≥400 mL, or use of blood products within 3 months prior to screening or between screening and dosing.
  • History of drug abuse (e.g., morphine, ketamine, tetrahydrocannabinolic acid, methamphetamine, methylenedioxymethamphetamine, cocaine) or positive urine drug test at screening.
  • History of needle phobia or hemophobia, difficulty with blood collection, or inability to tolerate venipuncture.
  • Any other condition (medical, psychological, psychiatric, social, or geographic factors) that, in the investigator's opinion, makes the participant unsuitable for the study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Group 1 - Healthy Control

    Drug: HDM1005

  • Experimental
    Group 2 - Moderate Renal Impairment

    Drug: HDM1005

  • Experimental
    Group 3 - Severe Renal Impairment

    Drug: HDM1005

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Concentration (Cmax)

    Cmax of HDM1005

    Time frame: Up to Day 29

  2. Area Under the Concentration Time Curve From Time Zero to t [ AUC(0- t)]

    AUC(0- t) of HDM1005

    Time frame: Up to Day 29

Secondary outcomes

  1. Apparent clearance (CL/F)

    CL/F of HDM1005

    Time frame: Up to Day 29

  2. Apparent distribution(Vz/F)

    Vz/F of HDM1005

    Time frame: Up to Day 29

  3. Adverse events (AEs)

    Number of subjects reporting AEs

    Time frame: Up to Day 29

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2026; primary completion for Jun 2026, 0 months later.

Of 211 industry-sponsored phase 1 interventional studies under Overweight, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's planned 0 months is below that.

Counting every sponsor, half of 230 studies reached it within 9 months; a quarter within 5 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2026
First posted
Apr 30, 2026
StartEst.
May 15, 2026
Primary completionEst.
Jun 12, 2026
CompletionEst.
Jul 31, 2026
Last update
May 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07559240
Responsible party
Sponsor
First posted
Apr 30, 2026
Start date
May 15, 2026 (estimated)
Primary completion
Jun 12, 2026 (estimated)
Completion
Jul 31, 2026 (estimated)
Last update
May 8, 2026

Study contacts

Guiyu Liu
Contact
liuguiyu@eastchinapharm.com
+86-0571 89908523

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HDM1005

Start the discussion